- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04603365
Pamiparib and Temozolomide for the Treatment of Hereditary Leiomyomatosis and Renal Cell Cancer
A Phase 2 Study of Pamiparib (BGB-290) Plus Temozolomide for Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC)
Study Overview
Status
Conditions
- Metastatic Renal Cell Carcinoma
- Stage IV Renal Cell Cancer AJCC v8
- Papillary Renal Cell Carcinoma
- Collecting Duct Carcinoma
- Unresectable Renal Cell Carcinoma
- Hereditary Leiomyomatosis and Renal Cell Carcinoma
- Clear Cell Papillary Renal Neoplasm
- Hereditary Papillary Renal Cell Carcinoma
- Metastatic Unclassified Renal Cell Carcinoma
- Stage III Renal Cell Cancer American Joint Committee on Cancer (AJCC) v8
- Tubulocystic Renal Cell Carcinoma
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVE:
I. Evaluate response rate of pamiparib plus low-dose temozolomide.
SECONDARY OBJECTIVES:
I. To evaluate the progression-free survival with pamiparib plus low-dose temozolomide.
II. To evaluate the safety (adverse events [AE's]) with pamiparib plus low-dose temozolomide.
TRANSLATIONAL OBJECTIVES:
I. To determine the association between plasma and tumor 2-hydroxyglutarate (2HG), fumarate, and succinate levels and response to treatment.
II. To analyze the association of the genomic mutational signature (by whole genome sequencing) of the tumor to treatment.
OUTLINE:
Patients receive orally (PO) twice daily (BID) on days 1-28 and temozolomide PO once daily (QD) on days 1-7. Cycles repeat every 28 days for up to 36 months in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 4 months.
Study Type
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Ankush Sachdeva
- Phone Number: 310 794-3421
- Email: asachdeva@mednet.ucla.edu
Study Locations
-
-
California
-
Los Angeles, California, United States, 90095
- Recruiting
- UCLA / Jonsson Comprehensive Cancer Center
-
Contact:
- Brian Shuch
- Phone Number: 310-794-1183
- Email: BShuch@mednet.ucla.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Subject has voluntarily agreed to participate by signing an informed consent
- Eastern Cooperative Oncology Group (ECOG) performance status of =< 1
- Ability to swallow whole capsules
- Histologically confirmed metastatic or unresectable renal cell carcinoma with morphologic features consistent with hereditary leiomyomatosis and renal cell cancer (HLRCC). This can include tumors with overlapping morphology previously called papillary, tubulocystic, tubulopapillary, collecting duct, or unclassified as long as in the HLRCC- spectrum
- The presence of a documented germline fumarate hydratase (FH) alteration (mutation or deletion). This includes pathogenic or likely pathogenic alterations but may also include variants of unknown significance (VUS) in patients with strong personal or family history where the clinician makes a presumed clinical diagnosis
- Progression on 1 or more lines of systemic therapies for metastatic disease. Neo/adjuvant therapy in the absence of documented distant disease does not count as a line of therapy
- No known intolerance of study drugs or excipients, and able to comply with study requirements
- Absolute neutrophil count (ANC) >= 1,500 /microliter (mcL) (< 2 weeks prior to day 1)
- Platelets >= 100,000 / mcL (< 2 weeks prior to day 1)
- Hemoglobin >= 10 g/dL or >= 6.2 mmol/L without transfusion or erythropoietin (EPO) dependency (within 2 weeks of first dose)
Serum creatinine =< 1.5 x upper limit of normal (ULN) OR measured or calculated creatinine (glomerular filtration rate [GFR] can also be used in place of creatinine or creatinine clearance [CrCl]) >= 40 mL/min for participants with creatinine levels > 1.5 x institutional ULN (< 2 weeks prior to day 1)
- Creatinine clearance should be calculated using the standard Cockcroft and Gault equation
- Total serum bilirubin =< 1.5 x ULN (total bilirubin must be < 4 x ULN for subject with Gilbert's syndrome) (< 2 weeks prior to day 1)
- Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 3 x ULN OR =< 5 x ULN for participants with liver metastases (< 2 weeks prior to day 1)
- International normalized ratio (INR) or prothrombin time (PT), and activated partial thromboplastin time (aPTT) =<1.5 x ULN unless participant is receiving anticoagulant therapy, and then only as long as PT or PTT is within therapeutic range of intended use of anticoagulants (< 2 weeks prior to day 1)
- Female patients of childbearing potential and female partners of male study patients must agree to practice highly effective methods of birth control for the duration of the study and for >= 6 months after the last dose of study drug. In addition, non-sterile male patients must agree to practice highly effective methods of birth control and avoid sperm donation for the duration of the study and for >= 6 months after the last dose of study drug
- From the time of the first study-drug treatment through 180 days after the last study drug treatment, male participants must use a condom when 1) having sex with a pregnant woman AND 2) having sex with a woman of childbearing potential
- Male and female participants must agree not to donate sperm or eggs, respectively, from the first study-drug treatment through 180 days after the last study drug treatment
- Female participants must agree to not breastfeed during the study or for 180 days after the last dose of study treatment
- If available, agreement to provide archival tumor tissue for exploratory biomarker analyses
- Willingness to undergo a fresh tumor biopsy if deemed safe and feasible by the investigator
Exclusion Criteria:
- Known hypersensitivity to any temozolomide (TMZ) component
- Prior treatment with a PARP inhibitor
- Received chemotherapy, biologic therapy, immunotherapy, or investigational agent within 3 weeks (or =< 5 half-lives, whichever is shorter) prior to cycle 1/day 1
- Have any unresolved acute effects of any prior therapy of grade 2 or higher, except for AEs not constituting a safety risk by investigator judgment
- Had a major surgical procedure (per investigator discretion) =< 4 weeks prior to cycle 1/day 1, or anticipation of need for major surgical procedure during the course of the study
Have other diagnosis of malignancy
- Except for surgically excised non-melanoma skin cancer, adequately treated carcinoma in situ of the cervix, localized prostate cancer treated with curative intent, adequately treated low-stage bladder cancer, ductal carcinoma in situ treated surgically with curative intent, or a malignancy diagnosed > 2 years ago, with no current evidence of disease and no therapy =< 2 years prior to day 1
- Subject who has received local radiotherapy of non-target lesions for local symptom control within the last 4 weeks must have recovered from any adverse effects of radiotherapy before recording baseline symptoms
- Have untreated leptomeningeal or brain metastasis. Subject with previously treated brain metastases is eligible if the metastases have shown no progression on brain computed tomography (CT) or magnetic resonance imaging (MRI) over at least 4 weeks, the subject has no symptoms due to the brain metastases, and the subject has been off corticosteroids for >= 2 weeks
- Have active infection requiring systemic treatment
- Have known human immunodeficiency virus (HIV) infection
- No known chronic active liver disease or evidence of acute or chronic hepatitis B virus (HBV) or hepatitis C (HCV) infection. Patients with prior curative treatment of hepatitis C virus are allowed if treated > 2 weeks prior to treatment previously and HCV ribonucleic acid (RNA) undetectable by established laboratory values
Have any of the following cardiovascular criteria:
- Current evidence of cardiac ischemia
- Current symptomatic pulmonary embolism
- Acute myocardial infarction =< 6 months prior to cycle 1/ day 1
- Heart failure of New York Heart Association classification III or IV =< 6 months prior to cycle 1/ day 1
- Grade >= 2 ventricular arrhythmia =< 6 months prior to cycle 1/ day 1
- Cerebral vascular accident (CVA) =< 6 months prior to cycle 1/ day 1
Have an active inflammatory gastrointestinal disease, chronic diarrhea, known diverticular disease or had previous complete gastric resection or lap band surgery
- Gastroesophageal reflux disease under treatment with proton pump inhibitors is allowed (assuming no drug interaction potential)
- Use or have anticipated need for food or drugs known to be strong or moderate cytochrome P450 (CYP)3A inhibitors or strong CYP3A inducers =< 10 days (or =< 5 half-lives, whichever is shorter) prior to day 1
- Are pregnant or nursing (females of childbearing potential require a negative serum pregnancy test =< 7 days before day 1)
- Requirement for intravenous (IV) alimentation (at the time of randomization)
- Known history of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML)
- Participants must not have received colony stimulating factors (e.g., granulocyte colony-stimulating factor, granulocyte macrophage colony stimulating factor, or recombinant erythropoietin) within 4 weeks prior initiating protocol therapy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment (pamiparib, temozolomide)
Patients receive PO BID on days 1-28 and temozolomide PO QD on days 1-7.
Cycles repeat every 28 days for up to 36 months in the absence of disease progression or unacceptable toxicity.
|
Given PO
Other Names:
Given PO
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Response rate
Time Frame: Up to 36 months of treatment
|
Defined as total number of subjects with confirmed responses of either complete response (CR) or partial response (PR) divided by the total number of subjects in the response-evaluable population per Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 by investigator assessment.
Response rate will be calculated along with the corresponding exact one-sided 95% Clopper-Pearson confidence interval.
|
Up to 36 months of treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-free survival (PFS)
Time Frame: From the first dose of study drug to the date of progressive disease first documented disease progression per RECIST v1.1 or death due to any cause by investigator assessment, whichever occurs first, assessed up to 3 years after completion of treatment
|
PFS will be summarized using the Kaplan Meier method as well as descriptively (mean, standard deviation, median, first and third quartiles, minimum, maximum).
Figures showing the Kaplan-Meier estimates will also be presented.
|
From the first dose of study drug to the date of progressive disease first documented disease progression per RECIST v1.1 or death due to any cause by investigator assessment, whichever occurs first, assessed up to 3 years after completion of treatment
|
Incidence of adverse events (AEs)
Time Frame: Up to 36 months
|
Safety profile including AE and serious (S)AEs will be reported.
Simple descriptive statistics will be used to summarize toxicities in terms of type, severity (by Common Terminology Criteria for Adverse Events [CTCAE] v4.03 toxicity table) and minimum or maximum values for laboratory measures, time of onset, duration, and reversibility or outcome.
Tables will be created to summarize these toxicities and side effects.
Adverse events will be tabulated and will include the number of patients for whom the event occurred, the rate of occurrence, and the severity and relationship to study drug.
|
Up to 36 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Plasma and tumor 2-hydroxyglutarate (2HG), fumarate, and succinate levels
Time Frame: Up to 36 months
|
Plasma and tumor samples will be subjected to multiplex liquid chromatography coupled with tandem mass spectrometry.
Will determine the association between plasma and tumor 2HG, fumarate, and succinate levels and response to treatment.
|
Up to 36 months
|
Genomic mutational signature (by whole genome sequencing)
Time Frame: Up to 36 months
|
Tumor material will be subjected to whole genome sequencing to determine the mutational spectrum.
Will analyze the association of the genomic mutational signature of the tumor to treatment.
|
Up to 36 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Brian Shuch, MD, UCLA / Jonsson Comprehensive Cancer Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms, Connective and Soft Tissue
- Neoplasms by Histologic Type
- Neoplasms
- Urologic Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Kidney Diseases
- Urologic Diseases
- Adenocarcinoma
- Neoplasms, Glandular and Epithelial
- Neoplasms, Muscle Tissue
- Leiomyoma
- Kidney Neoplasms
- Carcinoma, Renal Cell
- Carcinoma
- Leiomyomatosis
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Temozolomide
- Poly(ADP-ribose) Polymerase Inhibitors
Other Study ID Numbers
- 20-001106
- NCI-2020-05351 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic Renal Cell Carcinoma
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingMetastatic Renal Cell Carcinoma | Metastatic Clear Cell Renal Cell Carcinoma | Advanced Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Metastatic Sarcomatoid Renal Cell Carcinoma | Advanced Renal Cell Carcinoma | Unresectable Renal Cell... and other conditionsUnited States
-
NewLink Genetics CorporationCompletedMetastatic Renal Cell Carcinoma | Recurrent Renal Cell Carcinoma | Metastatic Kidney Cancer | Refractory Renal Cell Carcinoma | Metastatic Clear-cell Renal CancerUnited States
-
iOMEDICO AGNovartis PharmaceuticalsCompletedCarcinoma, Renal Cell | Clear-cell Metastatic Renal Cell Carcinoma | Locally Advanced and/or Metastatic Renal Cell CarcinomaGermany
-
Centre Hospitalier Universitaire de Saint EtienneTerminatedMetastatic Renal Cell Carcinoma | Metastatic Kidney CancerFrance
-
Roswell Park Cancer InstituteIovance Biotherapeutics, Inc.WithdrawnMetastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Unresectable Renal Pelvis Urothelial Carcinoma | Unresectable Ureter Urothelial CarcinomaUnited States
-
National Cancer Institute (NCI)RecruitingStage IV Renal Cell Cancer AJCC v8 | Sarcomatoid Renal Cell Carcinoma | Stage IV Bladder Cancer AJCC v8 | Stage IV Urethral Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Bladder Adenocarcinoma | Chromophobe Renal Cell Carcinoma | Papillary Renal Cell Carcinoma | Collecting Duct Carcinoma | Bladder... and other conditionsUnited States, Puerto Rico
-
Duke UniversityCompletedMetastatic Renal Cell Carcinoma | Metastatic Urothelial Carcinoma | Metastatic Castration-resistant Prostate Cancer (mCRPC)United States
-
Prometheus LaboratoriesCompletedMetastatic Renal Cell Carcinoma | Metastatic MelanomaUnited States
-
Association Pour La Recherche des Thérapeutiques...CompletedClear-cell Metastatic Renal Cell Carcinoma | Clear-cell Renal CarcinomaFrance
-
National Cancer Institute (NCI)RecruitingClear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Metastatic Malignant Neoplasm in the Bone | Metastatic Malignant Neoplasm in the Lymph Nodes | Metastatic Malignant Neoplasm in the Soft Tissues | Metastatic Malignant Neoplasm in the Viscera and other conditionsUnited States, Puerto Rico
Clinical Trials on Pamiparib
-
BeiGeneCompletedAdvanced Solid TumorsUnited Kingdom
-
Peter MacCallum Cancer Centre, AustraliaRecruiting
-
Fudan UniversityRecruitingLimited Stage Small Cell Lung CancerChina
-
BeiGeneTerminatedMetastatic Castration-Resistant Prostate Cancer (mCRPC) | Homologous Recombination Deficiency (HRD)United States, Australia, Puerto Rico, Spain
-
Australia New Zealand Gynaecological Oncology GroupBeiGeneWithdrawn
-
Bai-Rong XiaRecruiting
-
BeiGeneCompletedHER2-negative Breast CancerChina
-
Sun Yat-sen UniversityRecruitingMetastatic Castration-resistant Prostate CancerChina
-
BeiGeneActive, not recruiting
-
BeiGene USA, Inc.CompletedBrain and Central Nervous System TumorsUnited States, Netherlands, Switzerland